Ral-binding protein 1 (RALBP1) mRNA (RALBP1 mRNA)

Ral-binding protein 1 (RALBP1) mRNA, commonly referred to as RLIP76 mRNA, is a therapeutic target primarily investigated for its role in oncology and multidrug resistance. The protein encoded by this mRNA, RLIP76, is a multifunctional non-ABC transporter that facilitates the ATP-dependent efflux of glutathione-conjugated electrophiles and various chemotherapeutic agents, such as doxorubicin and vincristine [3, 4]. Beyond its transport capabilities, RLIP76 serves as a critical downstream effector for Ral GTPases, participating in clathrin-dependent endocytosis, mitochondrial fission, and the regulation of signal transduction pathways including JAK2/STAT3 and Rac1-JNK [1, 12]. In many human malignancies, including lung, colon, and prostate cancers, RLIP76 is significantly overexpressed, contributing to tumor survival and resistance to radiation and chemotherapy [9, 13]. Therapeutic strategies targeting the mRNA, such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), aim to deplete RLIP76 levels, thereby inducing apoptosis and sensitizing tumors to conventional treatments [2, 7]. However, research also indicates that RLIP76 deficiency is linked to increased oxidative stress and mitochondrial dysfunction, which are associated with neurodegenerative processes similar to Alzheimer's disease [5, 11].

Other names

RLIP76 mRNARIP1 mRNARal-interacting protein 1 mRNADNP-SG ATPase mRNA76 kDa Ral-interacting protein mRNA

Antisense-mediated mRNA degradation or RNA interference leading to reduced protein expression